13 September 2020: Database Analysis
Nomogram for Predicting Breast Cancer-Specific Mortality of Elderly Women with Breast Cancer
Xunxi Lu 12ABCDEF* , Xiaoguang Li 1ADEFG* , Hong Ling 12DFG , Yue Gong 12ACD , Linwei Guo 12ACE , Min He 12DF , Hefen Sun 12DG , Xin Hu 12EFG*DOI: 10.12659/MSM.925210
Med Sci Monit 2020; 26:e925210
Table 3 Proportional subdistribution hazard model of probabilities of BCSD for patients in the training cohort.
| Characteristics | Coefficient | sdHR (95% CI) | P-value |
|---|---|---|---|
| Age | |||
| 65–74 | Reference | ||
| 75+ | 0.360 | 1.43 (1.30–1.58) | |
| Marriage | |||
| Unmarried | Reference | ||
| Married | −0.314 | 0.73 (0.65–0.82) | |
| Race | |||
| White | Reference | ||
| Black | 0.482 | 1.62 (1.38–1.90) | |
| Other* | −0.108 | 0.90 (0.74–1.09) | 0.280 |
| Histology | |||
| IDC | Reference | ||
| ILC | 0.100 | 1.11 (0.94–1.29) | 0.210 |
| Other** | −0.332 | 0.72 (0.63–0.82) | |
| Grade | |||
| I | Reference | ||
| II | 1.030 | 2.80 (2.33–3.37) | |
| III/IV | 1.980 | 7.25 (6.07–8.66) | |
| ER status | |||
| Negative | Reference | ||
| Positive | −1.107 | 0.33 (0.20–0.37) | |
| PR status | |||
| Negative | Reference | ||
| Positive | −0.969 | 0.38 (0.35–0.42) | |
| T stage | |||
| T1 | Reference | ||
| T2 | 1.383 | 3.99 (3.59–4.43) | |
| T3 | 2.130 | 8.41 (7.14–9.91) | |
| T4 | 2.506 | 12.30 (10.20–14.70) | |
| N stage | |||
| N0 | Reference | ||
| N1 | 1.245 | 3.47 (3.11–3.88) | |
| N2 | 1.472 | 4.36 (3.83–4.96) | |
| N3 | 1.589 | 4.90 (4.30–5.58) | |
| Surgery | |||
| BCS | Reference | ||
| Mastectomy | 1.035 | 2.81 (2.56–3.1) | |
| IDC – infiltrating ductal carcinoma; ILC – infiltrating lobular carcinoma; ER – estrogen receptor; PR – progesterone receptor; BCS – breast-conserving surgery; BCSD – breast cancer-specific death; OCSD – other cause-specific death; HR – subdistribution hazard ratio; CI – confidence interval; T – tumor stage; N – nearby lymph node stage. * Including American Indian/Alaskan native and Pacific Islander; ** including other histology of invasive breast cancer except IDC and ILC. | |||